Advances in Therapy

, Volume 23, Issue 1, pp 179–190 | Cite as

Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: A review of 5 clinical studies

  • Andy Suter
  • Silvia Bommer
  • Jordan Rechner


Extracts from the seed of the horse chestnut (Aesculus hippocastanum L.) have traditionally been used to treat patients with chronic venous insufficiency and to alleviate its associated symptoms, including lower leg swelling. The efficacy of preparations that contain horse chestnut seed extract (HCSE) is believed to be due largely to an inhibitory effect on the catalytic breakdown of capillary wall proteoglycans. Aesculaforce® is a fresh plant HCSE that is available as an oral tincture, as tablets (20 mg or 50 mg), and as topical gel. Four clinical trials in patients with chronic venous insufficiency and 1 study in patients with varicose veins demonstrated the effectiveness of these preparations through the objective measure of reduction in lower leg edema and the subjective alleviation of leg pain, heaviness, and itching. Safe, well tolerated, and acceptable to patients, the fresh plant HCSE preparation Aesculaforce offers a real alternative in the treatment of patients with mild to moderate venous insufficiency.


horse chestnut seed extract clinical trial chronic venous insufficiency edema varicose veins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organization.WHO Monographs on Selected Medicinal Plants. Geneva, Switzerland: WHO; 2002.Google Scholar
  2. 2.
    Eberhardt RT, Raffetto JD. Chronic venous insufficiency.Circulation. 2005; 111: 2398–2409.PubMedCrossRefGoogle Scholar
  3. 3.
    Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study.J Epidemiol Community Health. 1999; 53: 149–153.PubMedCrossRefGoogle Scholar
  4. 4.
    Kreysel HW, Nissen HP, Enghofer E. Erhöte Serumaktivitäten lysosomaler Enzyme bei Varikosis. Beeinflussung durch einen Rosskastaniensamenextrakt.Therapiewoche. 1983; 33: 1098–1104.Google Scholar
  5. 5.
    Kreysel HW, Nissen HP, Enghofer E. A possible role of lysosomal enzymes in the pathogenesis of varicosis and the reduction in their serum activity by Venostasin.VASA. 1983; 4: 377–382.Google Scholar
  6. 6.
    Enghofer E, Seibel K, Hammersen F. Die antiexsudative Wirkung von Rosskastaniensamenextrakt. Neue Ergebnisse zu ihrem Mechanismus.Therapiewoche. 1984; 34: 4130–4144.Google Scholar
  7. 7.
    Cebo B, Krupinska H, Mazur J, Czarnecki R. Pharmacological properties of saponin fractions obtained from domestic crude drugs:Saponaria officinalis, Primula officinalis andAesculus hippocastanum. Herba Polonica. 1976; 22: 154–162.Google Scholar
  8. 8.
    Damas P, Volon G, Damas J, Lecomte J. Sur l’action antioedème de l’escine.Bull Soc Roy Sci Liège. 1976; 45: 436–442.Google Scholar
  9. 9.
    Klemm J. Strömungsgeschwindigkeit von Blut in varikösen Venen der unteren Extremitäten. Einfluss eines Venentherapeutikums (Venostasin).München Med Wechenschr. 1982; 124: 579–582.Google Scholar
  10. 10.
    Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency.Cochrane Database Syst Rev. 2004; 2: CD003230.PubMedGoogle Scholar
  11. 11.
    Kalbfleisch W, Pfalzgraf H. Oedemprotektiva: äquipotente Dosierung: Rosskastanienextrakt und 0-β-hydroxyethylrutoside im Vergleich.Therapiewoche. 1989; 39: 3703–3707.Google Scholar
  12. 12.
    Rehn D, Unkauf M, Klein P, Jost V, Lücker PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency.Arzneimittelforschung. 1996; 46: 483–487.PubMedGoogle Scholar
  13. 13.
    Erler M. Rosskastaniensamenextrakt bei Therapie peripherer venöser Oedeme: ein klinischer Therapievergleich.Med Welt. 1991; 42: 593–596.Google Scholar
  14. 14.
    Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse chestnut seed extract therapy in patients with chronic venous insufficiency.Lancet. 1996; 347: 292–294.PubMedCrossRefGoogle Scholar
  15. 15.
    European Scientific Cooperative of Phytotherapy.Medicinal Uses of Plant Drugs. Exeter, Devon, UK: ESCOP; 1999.Google Scholar
  16. 16.
    Shah D, Bommer S, Degenring FH. Aesculaforce bei chronisch venöser Insuffizienz. Placebokontrollierte Doppelblind-Studie zum Nacjweis der Wirksamkeit und Verträglichkeit eines Phytotherapeutikums.Schweiz Z Ganzheitsmed. 1997; 9: 86–91.Google Scholar
  17. 17.
    Dickson S, Gallagher J, McIntyre L, Suter A, Tan J. An open study to assess the safety and efficacy ofAesculus hippocastanum tablets (Aesculaforce 50 mg) in the treatment of chronic venous insufficiency.J Herbal Pharmacother. 2004; 4: 19–32.CrossRefGoogle Scholar
  18. 18.
    Geissbühler S, Degenring FH. Treatment of chronic venous insufficiency with Aesculaforce vein gel.Schweiz Z Ganzheitsmed. 1999; 11: 82–87.Google Scholar
  19. 19.
    Pilz E. Ödeme bei Venenerkrankungen.Med Welt. 1990; 41: 1143–1144.Google Scholar
  20. 20.
    Rudofsky G. Ödemprotektive Wirkung und klinische Wirksamkeit von Rosskastaniensamenextrakt im Doppelblindversuch.Fortschr Med. 1986; 104: 47–48.Google Scholar
  21. 21.
    Erdlen F. Klinische Wirksamkeit von Venostasin retard im Doppelblindversuch.Med Welt. 1989; 40: 994–996.Google Scholar
  22. 22.
    Siebert U, Brach M, Srocyzynski G, Uberla K. Efficacy, routine effectiveness and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency.Int Angiol. 2002; 21: 305–315.PubMedGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2006

Authors and Affiliations

  • Andy Suter
    • 1
  • Silvia Bommer
    • 2
  • Jordan Rechner
    • 3
  1. 1.Medical DepartmentBioforce AGSwitzerland
  2. 2.Abt. MedizinBioforce AGRoggwilSwitzerland
  3. 3.Department of SurgeryHospital AlstättenAltstättenSwitzerland

Personalised recommendations